Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced that the Alpha Deal Group, LLC, a buy-side advisory firm, has initiated independent research coverage on Addex Therapeutics. Their research report highlights Addex uniquely positioned technology and pipeline, and concludes that due to past events and current market inefficiencies, Addex is trading at a significant discount to its intrinsic value.

"There is huge value in the assets of Addex which is not recognised by the market, commented Malvi Gupta, senior analyst at Alpha Deal Group. "Addex has been through some challenging times, but we believe they are poised to strongly rebound as it executes on its turnaround strategy."

Alpha Deal Groups views are based on the progress Addex has made in turning the company around following a shortfall in funding in 2013. Addex turnaround strategy is based on advancing its clinical stage programmes, dipraglurant for Parkinson's disease levodopa induced dyskinesia (PD-LID) and cervical focal dystonia, and ADX71441 for Charcot-Marie-Tooth type 1A neuropathy and addiction. In the past 12 months Addex has made significant progress in advancing its programmes in collaboration with patient advocacy groups including The Michael J. Fox Foundation for Parkinson's Research, the Dystonia Medical Research Foundation and the US Charcot-Marie-Tooth Association. Addex has also successfully collaborated with government and academic institutions to advance its preclinical programmes. Furthermore, ADX71149, a second clinical stage product is being developed by partner Janssen Pharmaceuticals Inc.

"We believe this second analyst report provides useful guidance to the investment community on the Addex investment case as we execute on our strategy to unlock the value of the Addex portfolio for our shareholders," commented Tim Dyer, CEO of Addex."